Cinacalcet

Product Details:

Purity Not less than 98% (Specifications vary by manufacturer)
Application Oral administration
CAS No 226256-56-0
Molecular Formula C22H22F3N
Grade Pharmaceutical Grade
Formulations Type Pharmaceutical
Formulations Form Tablet
Click to View more
Share Your Product:

Request to Call Back Send Inquiry

Cinacalcet Product Specifications

Treatments & Functions Used to treat hyperparathyroidism hypercalcemia associated with parathyroid carcinoma and secondary hyperparathyroidism in chronic kidney disease
CAS No 226256-56-0
Gender/Age Group Adults
Formulations Type Pharmaceutical
Application Oral administration
Storage Instructions Store at room temperature between 20C to 25C (68F to 77F) in a tightly closed container to protect from moisture
Dosage Guidelines 25 mg to 100 mg orally once daily with food or shortly after a meal depending on the treatment regimen
Purity Not less than 98% (Specifications vary by manufacturer)
Grade Pharmaceutical Grade
Molecular Formula C22H22F3N
Formulations Form Tablet
Volume N/A - Solid dosage form

Product Description

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium ontissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.